Work

Comparison of Nevirapine (NVP) Resistance in Ugandan Women 7 Days vs. 6–8 Weeks after Single-Dose NVP Prophylaxis: HIVNET 012

Year: 2004

Type: article

Source: AIDS Research and Human Retroviruses

DOI: 10.1089/0889222041217518

Authors: S.H. Eshleman, L.A. Guay, A. Mwatha, S.P. Cunningham, E.R. Brown, P. Musoke, F. Mmiro, J.B. Jackson

Institutions: Johns Hopkins Hospital, Fred Hutch Cancer Center, University of Washington, Makerere University

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development

Awards: STATISTICAL &CLINICAL COORDINATING CENTER (SC), G1174034350, G445713723, HPTN - CENTRAL LABORATORY, INTNL.VACC.EFFICACY TRIALS MASTER CONTRACT (IMC), Drug Resistance in Non-Subtype B HIV-1, MU-JHU HPTU TRIAL SITE - UGANDA, G774531759, G807554087

OpenAlex ID: W2252582782

FWCI: 7.199

Cites: 11

Cited by: 71

Related to: 10